• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    P

    Portsmouth Regional Hospital

    EST. 1884
    113论文总数
    2,316引用总数

    论文量&引用量时间轴

    机构学者

    论文(113)

    年份
    起
    –
    止
    排序
    1When Common Diagnoses Fail: CMV Pneumonitis Beyond Immunosuppression
    H. F. Barham, M. Alsarayreh, M. Dogra, K. Schultz

    Abstract Introduction Cytomegalovirus (CMV) pneumonitis is classically associated with immunocompromised patients, including transplant recipients or those with HIV or prolonged immunosuppression. Its occurrence in immunocompetent adults is exceedingly rare and often leads to diagnostic delay. We present a case of severe CMV pneumonitis in an immunocompetent patient with progressive hypoxemia despite standard therapies. Case Presentation 72-year-old man with coronary artery disease (status post CABG and PCI), left carotid stent, COPD, chronic interstitial lung disease, and obesity presented with right-sided weakness, numbness, and visual changes. During hospitalization, he developed worsening shortness of breath and hypoxia. Imaging revealed bilateral pulmonary infiltrates, and initial management targeted multifocalpneumonia and COPD exacerbation with antibiotics and corticosteroids (methylprednisolone 40 mgIV every 6 hours for 5 days, followed by a gradual taper). Despite therapy, his respiratory status deteriorated, requiring NIV with HFNC. COVID-19 and influenza PCR tests were negative. CTA chest ruled out pulmonary embolism. Urine pneumococcal and Legionella antigens were negative, and blood, sputum, and BAL cultures showed no growth. Bronchoscopy demonstrated multinucleatedgiant cells, raising suspicion for a viral etiology. CMV PCR and serology (IgM and IgG) were positive,confirming CMV pneumonitis. The patient had no history of immunosuppression or HIV infection.Given his worsening respiratory failure, ganciclovir was initiated after infectious disease consultation.His oxygenation gradually improved with supportive care and antiviral therapy. Discussion This case illustrates that CMV pneumonitis can occur in immunocompetent hosts, particularly in the setting of critical illness. The diagnosis should be considered when pneumonia fails to improve with standard antimicrobial or steroid therapy. While the role of antivirals such as ganciclovir remains uncertain in immunocompetent patients, treatment may be warranted in severe or progressive cases. Conclusion CMV pneumonitis, though rare in immunocompetent individuals, should remain in the differential diagnosis of refractory pneumonia. Early recognition and consideration of antiviral therapy can be crucial for recovery in severe presentations. This abstract is funded by: None

    2026AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE(2026)
    引用
    AI阅读
    加入学术空间
    2Granulomatous Cheilitis As the Presenting Manifestation of Widespread Crohn's Disease.
    Wyatt Nice,Ekta Gupta, Marcia Wills, George Kunnackal John

    Granulomatous cheilitis, a localized subset of orofacial granulomatosis, can rarely be the presenting symptom of Crohn's disease. It can appear before any gastrointestinal (GI) symptoms develop. Orofacial granulomatosis has been associated with more widespread granulomatous Crohn's disease, which tends to be more aggressive. We present a case of isolated granulomatous cheilitis progressing to diffuse granulomatous involvement of multiple portions of the upper and lower GI tract with eventual secondary loss of response to initial anti-tumor necrosis factor-α therapy, underscoring the need for these patients to be monitored very closely even in the absence of GI symptoms.

    2026ACG case reports journal(2026)
    引用
    AI阅读
    加入学术空间
    3Temporal Trends and Future Projections of Pulmonary Arterial Hypertension Epidemiological Burden in the United States: Analysis from the Global Burden of Disease 2023
    Abdalrahman Al-slaimieh,Rand Al-Huneidy, Haya Al-Ani, Farah Al-Bihari, Leen Al-Huneidy, Rahaf Mashal, Mohammad Shahin, Yahya Almazaraa, Mohammad Hajjiri, Abdallah Al-Ani

    Background: Pulmonary arterial hypertension (PAH) is a fatal chronic condition characterized by progressive pulmonary vascular remodeling, elevated pulmonary pressure, and ultimately progresses into right-sided heart failure. The prognosis of PAH remains poor despite significant therapeutic advances. Affecting an estimated 1% to 2% of the U.S adult population, this significant cause of morbidity and mortality is understudied and of which mortality burden is underdefined following the 2018 diagnostic threshold revisions. We conducted this study to investigate the epidemiological burden of PAH from 1990 to 2023 and project its trends from 2024 to 2040. Methods: Data on age-standardized incidence (ASIR), prevalence (ASPR), mortality (ASMR), and disability-adjusted life years (ASDR) were retrieved from the Global Burden of Disease (GBD) 2023. Temporal trends between 1990 and 2023 were explored using average annual percentage change (AAPC) and Jointpoint regression. ARIMA forecasting was applied to project future trends until 2040 per 100,000 persons. All analyses were conducted on R software (4.3.3). Results: Across the United States, ASIR increased from 0.27 (95%UI: 0.22 - 0.34) in 1990 to 0.31 (95%UI: 0.24 - 0.37), representing an 11.7% increase. ASIR for PAH demonstrated a significant upward trend (AAPC: 0.34; 95%CI: 0.31 - 0.37). This trend was mirrored across both sexes. However, females demonstrated a significantly higher upward trend in ASIR compared to males (AAPC Difference: -0.05; p <0.001). Conversely, ASPR decreased from 1.84 (95%UI: 1.51 - 2.25) in 1990 to 1.72 (95%UI: 1.40 - 2.11) in 2023, representing a 6% decrease. ASPR demonstrated a significant downward trend on jointpoint regression (AAPC: -0.19; 95%CI: -0.22 - -0.17). These trends were mirrored by sexes with no differences in margins of rates. Similarly, ASMR dropped by around 20% reaching 0.29 (95%UI: 0.22 - 0.36) in 2023 from 0.36 (95%UI: 0.28 - 0.44) in 1990. ASMR demonstrated a significant downward trend (AAPC: -0.51; 95%CI: -0.67 - -0.33), which was mirrored across males and females with no differences in margins of rates. Likewise, ASDR dropped by 27% across studied period with a significant downward (AAPC: -0.96; 95%CI: -1.15 - -0.77), mirrored across sexes. Projections for 2040 show a downward trend from ASIR (0.30 per 100,000), ASPR (1.61 per 100,000), ASDR (5.9 per 100,000), and ASMR (0.25 per 100,000). Conclusion: Our findings contrast the upward epidemiological trends reported by the CDC WONDER database. Similarly, there were minimal demographic differences in epidemiological burden, particularly across sexes. In isolation, these trends prove the efficacy of targeted risk interventions, precision diagnostics, and overall quality of care deployed in the U.S. However, the variance with other reports underscores our limited understanding of PAH’s burden and the need for multicentric longitudinal studies.

    2026Circulation(2026)
    引用
    AI阅读
    加入学术空间
    4Artificial Intelligence in Cardiology in the Current Era: a Narrative Review
    Avilash Mondal,Harshith Thyagaturu, Sahas Reddy Jitta, Binita Bhandari, Emmett Helsel, Megha Dogra, Kesar Prajapati, Karthik Gonuguntla

    Background and Objective:Artificial intelligence (AI) has transformed cardiovascular healthcare by influencing multimodal imaging, interventional procedures, and remote patient monitoring systems. The rapid growth of available evidence presents challenges for researchers to evaluate the quality of AI systems and their readiness for clinical application. The review examines current AI uses in cardiology by assessing methodological quality to pinpoint key factors for implementing effective AI models. Methods:We performed extensive search on MEDLINE/PubMed, Web of Science, Scopus, EMBASE for original research, clinical trials, and consensus/guideline statements, published in English from January 2015 through December 2025. Key Content and Findings:AI applied to electrocardiography (AI-ECG) technology shows practical success in clinical trials for detecting left ventricular systolic dysfunction (LVSD) and predicting atrial fibrillation (AF) from normal heart rhythms. AI in echocardiography performs automated view detection, chamber measurement, and assists novice users. Cardiac magnetic resonance (CMR) uses deep learning (DL) for reconstruction and inline perfusion analysis. Coronary computed tomography angiography (CCTA) employs automated coronary artery calcium (CAC)/plaque analysis and machine learning (ML)-based fractional flow reserve computed tomography (FFRct), while nuclear cardiology uses AI to reduce doses and enhance image quality. The cath lab benefits from AI-assisted intravascular imaging, which helps optimize percutaneous coronary intervention (PCI) planning, robotics systems that lower operator radiation exposure, and angiography-derived physiology [e.g., quantitative flow ratio (QFR)], enabling wire-free ischemia assessment with context-dependent value. Challenges to AI adoption include limited external validation data, unclear calibration methods, and gaps in addressing subgroup fairness, decision impact, and post-deployment performance monitoring. Conclusions:AI technology has advanced from experimental development to practical solutions for specific cardiology procedures that improve operational efficiency and standardization. Turning accuracy into patient benefits requires researchers to conduct external validation studies, prospective impact assessments, cost-effectiveness evaluations, equity-focused design, workflow integration, and ongoing governance systems. Implementing AI as an assistive tool will enhance healthcare accessibility, reduce unnecessary treatment disparities, and improve outcomes through clinical support, while automation continues to streamline routine tasks.

    2026Cardiovascular diagnosis and therapy(2026)
    引用
    AI阅读
    加入学术空间
    5Awake Prone Positioning Reduces Mortality, Intubation, and Hospital Stay in Acute Hypoxemic Respiratory Failure: a Systematic Review and Meta-Analysis of 6,164 Patients
    Miqdad Alsarayreh, Mostafa Hossam El Din Moawad, Husam Barham, Osamah Yousef Abdelkarim, Dina Riyadh Fahem Al-Janabi, Ibraheem M. Alkhawaldeh, Hamza A. Abdul-Hafez

    Acute hypoxemic respiratory failure (AHRF) is a major cause of morbidity and mortality and often requires advanced respiratory support. Awake prone positioning (APP) has emerged as a simple, low-cost intervention to improve oxygenation in non-intubated patients; however, its clinical effectiveness and safety remain uncertain. This systematic review and meta-analysis aimed to evaluate the effectiveness and safety of awake prone positioning in non-intubated adult patients with acute hypoxemic respiratory failure. A systematic search of PubMed, Scopus, and Web of Science was conducted from database inception to February 2026. Randomized controlled trials and observational comparative studies evaluating APP versus usual care were included. Primary outcomes were mortality, intubation, and length of hospital stay. Secondary outcomes included ICU stay, invasive mechanical ventilation, ICU admission, escalation of respiratory support, time to invasive ventilation, and adverse events. Risk of bias was assessed using ROB 2 for randomized trials and the Newcastle–Ottawa Scale for observational studies. Meta-analysis was performed using a random-effects model. Twenty-four studies involving 6,164 patients were included. APP significantly reduced mortality (OR = 0.60, 95

    2026BMC Anesthesiology(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 113 篇论文

    合作机构(100)

    和谐归国总医院合作论文 20
    达特茅斯 - 希区柯克医学中心合作论文 19
    Eastern Maine Medical Center,Eastern Maine Healthcare Systems合作论文 14
    University of Vermont Medical Center合作论文 13
    Central Maine Medical Center合作论文 9
    达特茅斯卫生政策与临床研究所实践合作论文 9
    盖泽尔医学院合作论文 9
    约翰斯·霍普金斯大学合作论文 5
    密歇根大学合作论文 5
    达特茅斯学院合作论文 5

    机构统计